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Abstract
MYOD is a master regulator of the skeletal myogenic program. But what regulates expression of Myod? More than 20 years 
ago, studies established that Myod expression is largely controlled by just two enhancer regions located within a region 24 kb 
upstream of the transcription start site in mammals, which regulate Myod expression in the embryo, fetus and adult. Despite 
this apparently simple arrangement, Myod regulation is complex, with different combinations of transcription factors acting 
on these enhancers in different muscle progenitor cells and phases of differentiation. A range of epigenetic modifications in 
the Myod upstream region also play a part in activating and repressing Myod expression during development and regeneration. 
Here the evidence for this binding at Myod control regions is summarized, giving an overview of our current understanding 
of Myod expression regulation in mammals.
Keywords Myod · Myogenesis · Mammalian embryo · Transcription factor · Epigenetic regulation
Introduction
Myogenic determination gene number 1 (Myod1, usually 
simply referred to as Myod) was isolated on account of to 
its ability to induce skeletal muscle differentiation in fibro-
blasts, and a variety of other non-skeletal muscle cells (Choi 
et al. 1990; Davis et al. 1987; Weintraub et al. 1989). Due 
to this ability to reprogramme other cells to muscle and 
because it is expressed in cells of the early muscle lineage, 
Myod is often referred to as a master regulator (Chan and 
Kyba 2013; Weintraub et al. 1989), although it should be 
noted that Myod expression is not sufficient to reprogramme 
all non-muscle cells (e.g. Albini et al. 2013).
Myod encodes a basic helix-loop-helix transcription 
factor belonging to a larger family of myogenic regulatory 
factors (MRFs) that together control determination and dif-
ferentiation of all skeletal muscle cells. Myogenic Factor 5 
(Myf5), Myogenic Regulatory Factor 4 (Mrf4, also known 
as Myf6) and Myod act to direct cells into the skeletal myo-
genic lineage (Kassar-Duchossoy et al. 2004; Rudnicki et al. 
1993). In the absence of all three factors myoblasts, and 
consequently skeletal muscles, do not form in the embryo 
(Kassar-Duchossoy et al. 2004; Rudnicki et al. 1993). While 
Myod and Myf5 can functionally substitute for each other to 
maintain myogenesis during development, in the absence 
of Myf5 and Myod, Mrf4 cannot drive fetal skeletal mus-
cle differentiation (Kassar-Duchossoy et al. 2004). Expres-
sion of a fourth MRF, Myogenin (Myog), which is required 
for terminal differentiation of skeletal muscle cells in the 
embryo, is induced by the other three MRFs (Hasty et al. 
1993; Nabeshima et al. 1993). Likewise, the MRFs regu-
late myogenesis in satellite cells, a stem cell population that 
mediates muscle homeostasis, growth and repair in adult 
muscle (reviewed in Zammit 2017).
Since MRFs act to drive myogenesis, their expression 
must be under strict spatiotemporal control during develop-
ment and regeneration. In the case of Myod, studies dating 
back over two decades have shown that its expression in the 
embryo and adult is controlled by two cis-regulatory ele-
ments located upstream of the transcription start site (TSS) 
together with a minimal promoter region (Asakura et al. 
1995; Chen et al. 2001, 2002; Faerman et al. 1995; Gold-
hamer et al. 1992, 1995; L’Honore et al. 2003; Tapscott et al. 
1992). These elements bind both activators and repressors 
of transcription in different combinations depending on the 
cell type. The locus is also subject to epigenetic regulation, 
with modification of histones, DNA methylation and inter-
action with noncoding RNA all contributing to the correct 
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regulation of expression. This review summarises the fac-
tors that have been shown to bind upstream of Myod and 
the evidence that they are involved in regulation of Myod 
expression in mammals.
Skeletal muscle development 
and regeneration
The muscles of the limbs and trunk are derived from somites, 
epithelial structures that bud off in a rostral-caudal sequence 
from the paraxial mesoderm (reviewed in Tajbakhsh and 
Buckingham 2000). In mouse, the first somite pair forms at 
around embryonic day 8 (E8) and there after a new pair of 
somites forms caudally every 2 h or so until approximately 
65 somites are formed (Forsberg et al. 1998; Tam 1981). The 
dorsal part of the somite forms the dermomyotome (DM), 
from which the dermis and skeletal muscle of the trunk and 
limbs will develop. Soon after the somite forms, progenitor 
cells at the edges (lips) of the DM migrate under the DM 
and form the myotome (Venters et al. 1999). Subsequently, 
the DM begins to lose its epithelial character and cells from 
the central portion of the DM also move into the myotome, 
contributing further to its growth (Relaix et al. 2005). Cells 
of the dorsomedial myotome will form the epaxial (back) 
muscles while those in the ventrolateral region will form 
hypaxial muscles—the diaphragm, limb and ventral body 
wall muscles. At the level of the limb buds, cells in vent-
rolateral lip of the DM migrate into the limbs, where they 
then proliferate and differentiate (Houzelstein et al. 1999). 
Muscles of the head are primarily derived from the cranial 
mesoderm, which comprises cells originating from the ante-
rior lateral plate, unsegmented paraxial mesoderm (rostral 
to the somite forming paraxial mesoderm) and prechordal 
mesoderm, although some neck, jaw and tongue muscle pro-
genitors migrate to the head from the most rostral (occipital) 
somites (Michailovici et al. 2015).
This wave of primary myogenesis is complete by approxi-
mately E14.5 in mouse and is closely followed by a sec-
ond, fetal, wave of myogenesis, where myoblasts proliferate 
and fuse with pre-existing primary myofibres or form de 
novo myofibres through fusion with each other. During this 
phase, which lasts until birth, some cells remain undiffer-
entiated, forming a pool of progenitors, or satellite cells, 
which become located under the basal lamina surrounding 
each myofibre. These satellite cells are quiescent in adult 
muscle, but can be induced to proliferate and differentiate 
in response to various stimuli, including exercise and injury 
(Relaix and Zammit 2012).
The first myogenic genes to be transcribed are Myf5 and 
Mrf4, in the DM and then the myotome, shortly followed by 
branchial arch expression. Myf5 expression is also activated 
in the limb muscle precursors following their migration to 
the limb (reviewed in Comai and Tajbakhsh 2014; Vicente-
García and Carvajal 2018). Expression of Myod follows 
Myf5 and continues in muscle cells until birth when expres-
sion is downregulated, although a low level of Myod tran-
scription endures in certain adult skeletal muscles. Expres-
sion of Myod is also reactivated in activated satellite cells 
during muscle regeneration.
Other models of myogenesis
In addition to in vivo investigation, many studies of myo-
genic development make use of cell lines that are easily 
differentiated to myotubes or which express high levels of 
MRFs. In particular, C2 cell line clones, such as C2C12 and 
C2.7, undergo proliferation in high serum growth conditions, 
but differentiate and form contractile myofibres when serum 
is limited. These cells most likely represent a model of satel-
lite cell differentiation, since they are derived from injured 
adult mouse muscle (Yaffe and Saxel 1977). In addition, 
Rhabdomyosarcoma cells are characterized by expression of 
MRFs, including Myod (Clark et al. 1991), and are a model 
for understanding regulation of MRFs (Taberlay et al. 2011).
Cis‑regulatory elements controlling Myod 
expression
Gene expression is regulated, in part, by enhancers, genomic 
regulatory elements that bind transcription factors, interact 
with target promoters, recruit RNA Polymerase II (RNAPII) 
and promote transcription. Since enhancers are functional 
even outside their endogenous context, reporter assays are 
often used to test their ability to activate gene expression in 
cell culture or transgenic animals.
A series of experiments using reporter assays in vitro and 
in vivo showed that at a region extending 24 kb upstream 
of the human MYOD gene can essentially recapitulate the 
endogenous Myod expression pattern in the mouse embryo, 
fetus, and adult muscle, including regenerating satel-
lite cells. Remarkably, a large amount of this expression is 
controlled by just two enhancers, which have come to be 
known as the Core Enhancer (CE) and the Distal Regulatory 
Region (DRR), together with a proximal regulatory region 
(PRR) immediately upstream of the transcription start site 
(TSS; Fig. 1a; Asakura et al. 1995; Chen et al. 2001, 2002; 
Faerman et al. 1995; Goldhamer et al. 1992, 1995; L’Honore 
et al. 2003; Tapscott et al. 1992).
The CE, which was first identified as a 258 bp region 
located 20 kb upstream of the TSS of the human MYOD 
gene, shows 89% sequence identity with a similar region 
23 kb upstream of the mouse Myod gene (Fig. 1a; Gold-
hamer et  al. 1995). The CE drives initiation of Myod 
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Fig. 1  Sequences that regulate Myod expression. a Schematic of a 
region 50 kb upstream of the Myod gene, including the core enhancer 
(CE, in red), the distal regulatory region (DRR, in blue) and the 
proximal regulatory region (PRR, in green) immediately upstream 
of the Myod transcription start site (TSS, black arrow). This region 
lies within a super enhancer, associated with high levels of transcrip-
tion factors occupancy, H3K27ac marks and multiple enhancer RNAs 
(eRNAs). One of these is an eRNA is transcribed from the CE that 
plays a role in regulating Myod expression through promoting chro-
matin accessibility at the Myod promoter. b Transcription factor 
binding sites for bHLH factors (E-box) including MYOD, MYF5, 
CLOCK, BMAL2, SIM2, MSC and TCF21 are shown in blue, for 
SIX and EYA factors in green (MEF3 site), for PITX2 in pink (Paired 
binding site) and for SRF/MEF2 in orange (CaRG box). Closed boxes 
show sites that have been shown to bind these factors in electromobil-
ity shift or other assays are shown as closed boxes, while open boxes 
show predicted sites. The E-box (closed) that binds CLOCK/BMAL2 
overlaps a PIXT2 binding site. A region that is PAX3 dependent in 
somites and limbs, and is required for expression in myotomally-
derived muscles, is indicated by the dashed purple line. (Color figure 
online)
expression in muscle precursor cells and nascent myocytes 
of the DM and myotome, branchial arches and limb buds in 
a pattern that mirrors the endogenous gene (Chen et al. 2001; 
Goldhamer et al. 1995). However, the CE is not sufficient 
for continued maintenance of reporter gene expression in 
differentiated skeletal muscle, since the transgene activity 
decreases during fetal and postnatal development until it 
becomes largely undetectable in adult muscle (Faerman et al. 
1995). Linker-scan mutagenesis of the CE reveals elements 
within it that are essential for expression in all skeletal mus-
cle progenitors, including the head, and separate elements 
that are required only for expression in the epaxial muscles 
and the hypaxial muscles of the body wall (Kucharczuk et al. 
1999).
Although sufficient to drive early expression, deletion of 
the CE within the context of the 24 kb MYOD reporter con-
struct results merely in reduced expression of the reporter in 
the hypaxial myotome together with a delay in expression in 
branchial arches and limb buds (Chen et al. 2001), indicating 
other regions in the 24 kb construct can compensate in part 
for the loss of the CE. Indeed, deletion of the CE within the 
mouse genome shows the CE is not absolutely required to 
initiate endogenous Myod expression in somites, since this 
does not change timing or pattern of expression, although 
it does lead to weaker expression of Myod. However, initia-
tion of Myod expression in branchial arch and limb buds is 
delayed, confirming the CE controls the timely initiation of 
Myod expression in these muscles (Chen and Goldhamer 
2004).
The DRR is a 714 bp region located approximately 5 kb 
upstream of mouse Myod, and also shares high sequence 
conservation with its human counterpart (Fig. 1a; Chen 
et  al. 2001; Tapscott et  al. 1992). In transgenic mouse 
reporter studies, the DRR drives expression at a later stage 
than the CE, in differentiated skeletal muscle cells of the 
myotome, head and limb (Asakura et al. 1995; Chen et al. 
2001; Kablar et al. 1997). In addition, it continues to drive 
reporter expression in adult skeletal muscle cells in a pat-
tern that resembles endogenous Myod expression (Hughes 
et al. 1993), and upregulation in activated satellite cells in 
regenerating muscle (L’Honore et al. 2003). Deletion of the 
DRR in the mouse genome causes a reduction of early Myod 
expression before cells differentiate, while later expression 
of Myod in the embryo and fetus is unaffected, results that 
are unexpected in light of the transgenic studies showing 
it drives expression in differentiated cells, and suggesting 
redundancy with other sequences in the Myod locus at later 
stages. However, the DRR is required to maintain levels of 
Myod expression in adult skeletal muscle, consistent with 
transgenic assays (Chen et al. 2002). Taken together these 
studies indicate that in general the CE is required for initia-
tion of Myod expression and the DRR with maintenance of 
expression and adult skeletal muscle expression, but that 
redundancy with each other and other regions exists.
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The PRR, which extends 275 bp upstream of the Myod 
TTS, is unable to direct specific expression of Myod, but 
acts as a minimal promoter in combination with the DRR 
or CE (Fig. 1a).
Transcription factor binding to Myod 
cis‑regulatory elements: activators
Despite a role for Myod in all skeletal muscle groups, genetic 
studies show that the factors acting upstream to regulate 
expression are varied and differ depending on the origin of 
the cells and the phase of muscle formation (reviewed in 
Buckingham 2017). Summarised below, for those factors 
that are implicated in direct regulation of Myod expression, 
is evidence for binding of these factors to the CE and DRR, 
and other regions within in the proximal upstream region 
of Myod.
MRFs and PAX3/PAX7
In the somites and limbs, Pax3 and Myf5 act in parallel path-
ways to regulate Myod expression during the first wave of 
myogenesis (Tajbakhsh et al. 1997). Pax3 expression pre-
cedes Myod in the DM and cells that migrate to the limb. 
Pax7 becomes expressed a little later in the central DM and 
plays a redundant role in embryonic myogenesis with Pax3. 
Indeed, although the early myotome forms in Pax3; Pax7 
mutant mice, no further muscle forms after this (Relaix 
et al. 2005). Consistent with this, Myod expression is almost 
completely absent in Pax3/Pax7 double mutant embryos at 
later embryonic stages (E13.5; Relaix et al. 2005).
As mentioned above, Myf5 and Mrf4 expression also 
precedes Myod expression. While loss of Myf5 alone does 
not impact Myod expression, loss of Myf5 and Mrf4, in a 
mutant where targeted disruption of the Myf5 locus also 
results in lack of Mrf4 expression due to the genes being 
closely adjacent to each other (henceforth referred to as 
Myf5(Mrf4) mutants), causes an approximately 2-day delay 
in expression of Myod in the somites (Kablar et al. 1997; 
Kassar-Duchossoy et al. 2004; Tajbakhsh et al. 1997). Simi-
larly, loss of Pax3 alone does not affect Myod expression, 
whereas Pax3;Myf5(Mrf4) mutants do not express Myod in 
somites and limb, indicating these factors compensate for 
each other in regulating Myod in the trunk of the embryo 
(Kassar-Duchossoy et al. 2004; Fig. 2). Craniofacial Myod 
expression on the other hand is seen in these mutants, since 
Pax3 is not expressed in cranial mesoderm, although Pax7 
is (Tajbakhsh et al. 1997; Fig. 2). Instead, PITX2 and other 
transcription factors play a role in regulating Myod expres-
sion in the head mesoderm (see sections below).
A subset of Pax3/Pax7 expressing cells from the embry-
onic somites will become adult satellite cells and continue 
to express Pax7, which is required for satellite cell function 
in muscle homeostasis and regeneration (Kuang et al. 2006; 
Oustanina et al. 2004; Relaix et al. 2006; von Maltzahn 
et al. 2013). Pax7 is able to activate the expression of Myod, 
and after satellite cell activation both Myf5 and Myod are 
required for normal muscle regeneration, since when Myf5 
and Myod are together knocked out in adult muscle, satellite 
Fig. 2  Transcription factor 
binding and regulation of Myod 
in different cell types. Factors 
that regulate Myod expression 
and have been shown to bind 
the CE, PRR, DRR or adjacent 
regions are shown for different 
cells types. See text and Table 1 
for details
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cells fail to reliably enter the myogenic pathway and do not 
differentiate (Gayraud-Morel et al. 2007; Megeney et al. 
1996; Ustanina et al. 2007; Yamamoto et al. 2018; Zammit 
et al. 2006).
Linker-scan mutagenesis of the CE suggests a region near 
the 3′ end (LS14 and 15, Kucharczuk et al. 1999) is depend-
ent on PAX3 activity in the somites and limbs (Fig. 1b), 
however, direct binding of PAX3 (or PAX7) had not been 
shown at the CE, or indeed the DRR, which may indicate 
these regions are indirectly regulated by PAX3/PAX7. 
However, several cell-based studies have shown binding of 
PAX/PAX7 to Myod upstream regions other than the CE or 
DRR. In myoblasts transfected with tagged PAX3 or PAX7, 
PAX7 was shown by chromatin immunoprecipitation (ChIP) 
to bind approximately 40 kb upstream of the TSS (Fig. 2; 
Table 1; Soleimani et al. 2012a). Other experiments using 
an antibody which recognises both PAX3 and PAX7 showed 
that in partnership with FOXO3, PAX3/PAX7 binds a region 
between − 1.5 and − 1.6 kb upstream of the Myod TSS to 
synergistically regulate Myod expression (Table 1; Fig. 2; 
Hu et al. 2008). This binding is associated with increased 
recruitment of RNAPII to the Myod promoter (Hu et al. 
2008). FOXO3 is further implicated as a regulator of endog-
enous Myod expression, since in mice mutant for Foxo3, 
Myod is down-regulated in regenerating muscle (Fig. 2; Hu 
et al. 2008).
MYF5, MRF4, and MYOD itself, regulate the expres-
sion of Myod through the DRR, since the DRR cannot 
drive reporter gene expression in Myod;Myf5(Mrf4) mutant 
embryos (Kablar et al. 1999). In these embryos the CE 
drives weak expression in the somites and delayed expres-
sion in the limb (Kablar et al. 1999). MYOD can also regu-
late its own expression in vitro via binding E-boxes, bind-
ing sites for bHLH factors, in the promoter region of Myod 
(Fig. 2; Table 1; Zingg et al. 1994). Although the DRR and 
CE contain E-boxes, direct binding of MRFs has not been 
shown as yet in embryos and whether these factors differ-
entially bind to the CE and DRR is not known. However, 
several genome-wide studies have shown MYOD and MYF5 
bind the CE and/or the DRR and adjacent sites in myoblasts 
in culture, although occupancy at these sites differs depend-
ing on the cell type and specific assay, so how this binding 
translates to functional regulation is still to be investigated 
(Table 1; Conerly et al. 2016; Cui et al. 2017; Mousavi et al. 
2013; Soleimani et al. 2012b; Umansky et al. 2015).
SIX and EYA
Six homeodomain (SIX) transcription factors and their co-
factors, members of the Eyes absent (EYA) family, are also 
upstream regulators of Myod in both trunk and head skeletal 
muscle. Mice mutant for Six1/4 or Eya1/2 show a reduction 
in Myod expression in muscle precursor cells of the somite 
and limb (Grifone et al. 2007; Laclef et al. 2003). Both the 
CE and DRR bind SIX1/SIX4 and SIX2 in vitro and EYA 
proteins in vivo (Table 1; Fig. 2; Liu et al. 2010; Relaix 
et al. 2013), and consistent with a direct role in regulating 
the CE, when SIX binding sites in the CE are mutated, the 
CE is unable to drive robust reporter expression in the trunk 
(Relaix et al. 2013). Despite expression of Myod in the head 
in Six1/4 and Eya1/2 mutants, mutation of the SIX binding 
sites in the CE results in loss of reporter expression in the 
head. This suggests another SIX factor, likely to be SIX2, 
activates expression of Myod in the head in the absence of 
Six1 and Six4 (Fig. 2; Relaix et al. 2013). SIX1 also appears 
to regulate Myod expression in regenerating adult muscles 
cells, since SIX1 is bound to the DRR in differentiating 
satellite cells derived from adult mouse, and when SIX1 
activity is knocked down in these cells Myod expression is 
reduced (Table 1; Fig. 2; Le Grand et al. 2012).
PITX2
PITX2, a paired-like homeodomain protein, is another factor 
that regulates Myod expression in both the trunk and head 
(Diehl et al. 2006; Dong et al. 2006; L’Honore et al. 2010). 
In the limb and myotome PITX2 cooperates with MYF5 and 
MYF4 to regulate Myod expression, while in the extraocular 
eye muscles of the head it acts upstream of Myf5 and Mrf4 
(reviewed in Hernandez-Torres et al. 2017). PITX2 binds the 
CE (but not the DRR) in hindlimb buds and is able to acti-
vate expression of a reporter gene in cell based assays, while 
mutation of two paired binding sites within the CE abolishes 
the reporter activity (Table 1; L’Honore et al. 2010), indicat-
ing PITX2 binding to the CE is required for limb expression. 
In contrast, myotomal expression of Myod does not require 
Pitx2, but in Pitx2;Myf5(Mrf4) mutants almost all myotomal 
Myod expression is absent, suggesting redundancy between 
these factors (L’Honore et al. 2010). In support of a direct 
role in regulating MyoD expression in somites, chromatin 
immunoprecipitation experiments show PITX2 binding to 
the CE, DRR and just upstream of the PRR in mouse embry-
onic myotome (Table 1; Fig. 2; L’Honore et al. 2010). In the 
head conditional inactivation of Pitx2 in the extraocular eye 
muscle precursors results in downregulation of Myod expres-
sion. ChIP of PITX2 in C2C12 cells and in an extraocu-
lar eye muscle derived cell line indicates that PITX2 binds 
the PRR but not the CE (the DRR was not tested; Table 1; 
Fig. 2; Zacharias et al. 2011). These data indicate that Myod 
expression is regulated through PITX2 binding a different 
combination of regulatory regions in the limbs (CE) com-
pared to the myotome (CE, DRR, upstream of the PRR) 
and extraocular eye muscles (PRR), although how PITX2 
discriminates is currently unknown.
 Journal of Muscle Research and Cell Motility
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MUSCULIN and TCF21
The bHLH transcription factors, MUSCULIN (MSC; also 
known as MYOR) and TCF21 (CAPSULIN) are together 
required for formation of some first branchial arch-derived 
skeletal muscles, where they are transiently expressed (Lu 
et al. 2002). Myod expression is absent in these cells in 
Msc/Tcf21 mutants and both factors bind the PRR and DRR 
(but not the CE) in E10.5 branchial arch cells, suggesting 
they directly regulate Myod expression (Table 1; Fig. 2; 
Moncaut et al. 2012).
GLI2
Sonic hedgehog (Shh) signalling, which is mediated by the 
activating transcription factors GLI1 and GLI2, plays a role 
in regulating Myod expression both in the embryo and in 
regenerating muscle. Shh is required for expression of Myod 
in the epaxial myotome and limb and for initiation of Myod 
expression in the limb (Borycki et al. 1999; Hu et al. 2012). 
It is also required for the upregulation of Myod in activated 
satellite cells (Straface et al. 2009). In a cell culture model in 
which P19 cells are differentiated to myotubes, GLI2 activity 
was found to regulate Myod expression, possibly through 
GLI2 binding to sites ~  35 kb upstream of the CE and ~ 1 kb 
upstream of the MyoD TSS (Table 1; Voronova et al. 2013), 
raising the possibility that GLI2 directly regulates Myod 
expression in vivo.
SRF, MEF2 and cofactors
Serum response factor (SRF), a transcription factor of the 
MADS box family, plays a role in skeletal, cardiac and 
smooth muscle formation (reviewed in Coletti et al. 2016). 
In skeletal muscle it is not required for embryonic Myod 
expression and myogenesis, but plays a role in adult mus-
cle homeostasis. Members of the Myocardin family of 
transcription factors, including MRTF and MASTR, act 
as co-factors for SRF and MEF2 factors, also MADS box 
family members, respectively, and consequently also play 
important roles in muscle formation (Creemers et al. 2006; 
Olson and Nordheim 2010). MASTR and MRTF-A are up-
regulated in satellite cells in response to injury, and are 
required for differentiation of satellite cells during growth 
and regeneration in the adult (Mokalled et al. 2012). Con-
sistent with the DRR driving expression of Myod in adult 
muscle, all these factors bind the DRR (Table 1; Fig. 2). 
SRF binds to a divergent CArG box in the DRR, in com-
plexes that include YY1, a regulator of enhancer–promoter 
interactions, CBP, a transcriptional coactivator, C/EBP 
family factors and MRTF-A (Table 1; Fig. 2; L’Honore 
et al. 2003, 2007; Mokalled et al. 2012; Weintraub et al. 
2017). This CArG box is required for expression of a 
DRR-reporter construct in differentiating myoblasts in 
culture and in activated satellite cells after muscle lesion 
in vivo (L’Honore et al. 2003). The divergent CArG box 
is a combined MEF/SRF binding site and is also bound by 
a complex of MASTR and MEF2 family factors in myo-
blasts (Table 1; Fig. 2; L’Honore et al. 2007). It appears 
that a switch occurs as cells differentiate, such that while 
SRF binding initiates Myod expression, as cells differenti-
ate MEF2 binding replaces SRF and maintains expression 
(L’Honore et al. 2007).
CLOCK and BMAL1
In adult skeletal muscle, Myod mRNA exhibits circadian 
rhythm which is abolished in mice mutant for Clock or 
Bmal1, two bHLH-PAS domain transcription factors that 
heterodimerize to positively regulate the circadian clock 
through binding E-boxes in target gene loci. The CE is 
required to regulate periodic Myod expression in  vivo, 
and both CLOCK and BMAL1 bind the CE in muscle 
(Andrews et al. 2010; Zhang et al. 2012). This binding 
appears to be via a conserved non-canonical E-box in the 
CE (Fig. 1b; Table 1; Zhang et al. 2012), and consistent with 
the CE regulating periodic activation of Myod transcription, 
CLOCK and BMAL1 binding to the CE in cultured cells is 
most enriched when Myod transcripts are at their highest 
(Andrews et al. 2010).
Transcription factor binding to Myod 
cis‑regulatory elements: repressors
Myod expression must also be repressed in a controlled tem-
poral and spatial fashion. Reporter assays show that the DRR 
drives reporter gene expression in non-myogenic cells, sug-
gesting that repressor sequences may be found outside the 
DRR region (Asakura et al. 1995). Some linker-scan muta-
tions in the CE also result in ectopic expression, which sug-
gests the CE contains regions that bind repressors (Kucha-
rczuk et al. 1999). The evidence for repressor binding in the 
Myod upstream region is summarised below.
SIM2
The bHLH-PAS domain transcription factor, Sim2 is 
expressed in muscle progenitors shortly after they have 
migrated into the limb and before Myod expression is 
upregulated (Coumailleau and Duprez 2009; Havis et al. 
2012). In Sim2 mutants Myod expression in the limb is 
upregulated compared to wild type levels (Havis et al. 2012). 
Sim2 appears to prevent entry into the myogenic program 
through repression of Myod expression, since it binds to 
the CE in embryonic mouse limb buds and represses Myod 
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transcription when overexpressed in primary limb bud myo-
blasts (Table 1; Fig. 2; Havis et al. 2012).
DELTEX2
Deltex2, which encodes an E3 ubiquitin ligase, is expressed 
during regeneration in adult muscle in myogenic progeni-
tor cells and inhibits myogenic differentiation (Luo et al. 
2017). In cell differentiation assays, exogenously expressed 
DELTEX2 is able to bind the DRR and PRR, but not the CE 
(Table 1; Fig. 2), and leads to an enrichment of dimethyl 
lysine 9 of histone H3 (H3K9me2), a repressive chromatin 
mark, at the Myod TSS. This is likely to be through inhibit-
ing the activity of JMJD1C, a lysine demethylase (Luo et al. 
2017).
C/EBP homology protein
C/EBP homology protein (CHOP, also known as DDIT3) 
is expressed in quiescent satellite cells in vivo and is tran-
siently induced during myoblast differentiation in vitro 
(Alter and Bengal 2011; Fukada et al. 2007). Knockdown 
of CHOP in C2C12 cells results in premature expression of 
myogenic genes, and conversely overexpression of CHOP 
results in inhibition of the myogenic program and reduced 
nuclei numbers in myotubes that do form (Alter and Ben-
gal 2011). CHOP seems to act by binding at approximately 
3 kb upstream of the Myod TSS and repressing expression 
of Myod (Table 1; Fig. 2). Interestingly, this binding is 
associated with a decrease in Histone H4 acetylation (an 
active histone mark) near the DRR and may indicate CHOP 
acts through regulating the activity of a histone deacetylase 
(Table 1). Further evidence for this comes from experiments 
in 293 T cells where CHOP was shown to interact physi-
cally with Histone Deacetylase 1 (HDAC1; Alter and Bengal 
2011).
Epigenetic regulation of Myod regulatory 
regions
Whilst transcription factors direct the activation of gene 
expression, DNA must be accessible for them to bind. The 
accessibility of enhancer and promoter sequences to tran-
scription factor binding is controlled through multiple epi-
genetic mechanisms including DNA methylation, histone 
modification and interactions with non-coding RNAs, all of 
which are at play in Myod regulation.
Methylation
DNA methylation at cytosine (C) residues within CpG dinu-
cleotides is generally associated with repression of gene 
expression. It has long been known that treating a mouse 
embryonic fibroblast cell line (CHC3H 10T1/2) with 5-aza-
cytidine, which inhibits DNA methylation, can convert these 
cells to skeletal muscle, suggesting that DNA methylation is 
important in maintaining repression of myogenic genes in 
non-muscle cells (Constantinides et al. 1977). Indeed, DNA 
hypomethylation is associated with active enhancers (e.g. 
Blattler et al. 2014; Hon et al. 2013). This is seen at the 
CE, where studies in adult tissues and cell culture show that 
myoblasts and myotubes have low levels of methylation at 
the CE, while non-muscle tissues have higher levels (Brunk 
et al. 1996; Carrio et al. 2016; Ehrlich et al. 2016). Consist-
ent with this, in the mouse embryo the presomitic meso-
derm shows higher levels of methylation at the CE compared 
to the somites, with demethylation of CE preceding Myod 
expression (Brunk et al. 1996). However methylation of the 
CE may not be sufficient for repression of Myod expression, 
since a demethylated CE transgene is not activated preco-
ciously or ectopically, suggesting other mechanisms may 
also be responsible for active repression of Myod expres-
sion (Brunk et al. 1996).
Nucelosomes and histone modification
In eukaryotes, DNA is wrapped around a core complex of 
histone proteins, the nucleosome, helping to package long 
DNA molecules into the nucleus but reducing the accessibil-
ity of transcriptional machinery to the DNA. Modification, 
such as acetylation and methylation, of amino acids in the 
N-terminal tails of histones alter how tightly the DNA inter-
acts with the nucleosome and thereby regulates accessibility 
of transcription factor binding. As such nucleosome posi-
tion and histone modification at enhancers and promoters 
are important regulators of gene expression. For instance, 
genome-wide studies using chromatin immunoprecipitation 
of histones have shown active promoters and enhancers often 
contain nucleosome-depleted regions, while nucleosomes 
downstream of promoters are associated with high levels of 
Histone H3 lysine 4 tri methylation (H3K4me3), and nucle-
osomes at enhancer regions are preferentially marked by 
high levels of H3K4me1 (Bernstein et al. 2006; Heintzman 
et al. 2007, 2009; Rada-Iglesias et al. 2011). The presence of 
H3K27ac marks promoters and enhancers as transcription-
ally active, while H3K27me3, H3K9me2/3 and H4K20me3 
are associated with repressed genes (Creyghton et al. 2010; 
Heintzman et al. 2007, 2009; Rada-Iglesias et al. 2011; 
Wang et al. 2008; Young et al. 2011). Acetylation of lysine 
residues in the Histone H4 tail are also associated with tran-
scriptional activation (Wang et al. 2008).
These associations are reflected in studies of histone 
modification in muscle and non-muscle cells. Cell culture 
experiments show that myoblasts and myotubes both have 
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active histone marks at the Myod promoter, DRR and CE, 
as well as other regions upstream of these, as does skeletal 
muscle, while non-muscle tissues have repressive marks in 
the same region upstream of the Myod gene (Ehrlich et al. 
2016). For instance one study in a Rhabdomyosarcoma cell 
line, has shown that both the CE and the Myod TSS region 
are nucleosome free, and are associated with high levels 
of H3K4me1 and H3K4me3 respectively, while in colorec-
tal cancer cells, where Myod is not expressed, both the CE 
and promoter contain nucleosomes (Table 2; Taberlay et al. 
2011).
Enhancers are also often associated with P300, a tran-
scriptional coactivator that contains a histone acetyltrans-
ferease (HAT) domain (Visel et al. 2009). P300 binding at 
the CE, DRR and PRR is found to increase as myoblast cells 
differentiate towards myotubes in C2 cell culture, with a 
corresponding increase in H3K27ac and H3K9ac (transcrip-
tion elongation) levels (Table 2; Gates et al. 2017; Hamed 
et al. 2013). Whilst mouse mutants carrying an allele with 
reduced P300 HAT activity exhibit reduced Myod expres-
sion (Roth et al. 2003), suggesting that acetylation of his-
tones at Myod regulatory regions is required for robust 
expression.
In addition to modification of core histones, variant 
histone isoforms, which have particular regulatory func-
tions, are differentially incorporated into nucleosomes. For 
instance the Histone H3 variant, H3.3, is associated with 
active genes and enhancers (Ahmad and Henikoff 2002; Jin 
et al. 2009). At the Myod locus a study in C2 cells has shown 
that levels of H3.3 increase at the CE, DRR and PRR as 
myoblasts differentiate, and when levels of H3.3 are reduced 
at these regulatory regions through inhibiting the activity of 
the H3/H4 histone chaperone, Histone regulator A (HIRA), 
Myod transcription is reduced (Fig. 2; Yang et al. 2011), 
suggesting that transcription of Myod is facilitated by inte-
gration of Histone H3.3.
Few studies have looked at histone binding at the Myod 
locus in vivo, however Havis et al. (2012) showed that acety-
lated Histone H4 is present at the CE and PRR but not at the 
DRR in mouse embryos (Table 2). Interestingly, this reflects 
the situation seen in transgenic mice where the CE drives 
limb bud expression but the DRR does not (Asakura et al. 
1995; Chen et al. 2001; Goldhamer et al. 1995).
DNA looping
In active chromatin, loops of DNA are formed that bring 
the promoter and enhancer close together for activa-
tion of gene expression. The cohesion complex, which 
includes the RAD21 subunit, mediates this looping and 
thus many enhancers and promoters are associated with 
RAD21 binding. This is true of the Myod CE and promoter 
in Rhabdomyosarcoma cells, in which Myod is highly 
expressed, which are both associated with RAD21 binding 
(Fig. 2; Taberlay et al. 2011).
Heterochromatin
In quiescent satellite cells levels of heterochromatin, which 
represses gene activation, are high and decrease as cells are 
activated and enter the myogenic pathway (Hawke and Garry 
2001). In proliferating C2 cells, in which Myod expression 
is low, the CE is associated with high levels of H3K9me2/3 
(Scionti et al. 2017), while in satellite cells isolated from 
adult mouse muscle the DRR is associated with high lev-
els of H3K20me2, a substrate for further methylation to 
H3K20me3, which decrease as cells differentiate (Table 2; 
Boonsanay et al. 2016). This repression of Myod via deposi-
tion of H3K20me2 appears to be mediated by SUV4-20H1, 
a dimethyltransferase, since in satellite cells mutant for 
Suv4-20h1, Myod transcription increases while H3K20me2 
is reduced and H3K4me3 is increased at the DRR (Table 2; 
Boonsanay et al. 2016).
Unlike the other histones, H1 sits atop the nucleosome, 
keeping the DNA wrapped around the core histone complex, 
and thus also plays an important role in regulating accessi-
bility to the DNA (Izzo and Schneider 2016). During myo-
genesis, integration of the Histone H1b variant at the CE, 
mediated by binding of MSH Homeobox 1 (MSX1) and 
Y-box binding protein 1 (YB1) at the CE, is also associated 
with increased H3K9 methylation (Tables 1, 2; Lee et al. 
2004; Song and Lee 2010). This is consistent with the role of 
MSX1 in repression of muscle differentiation in the hypaxial 
DM and migrating limb muscle progenitor cells in the mouse 
embryo (Fig. 2; Houzelstein et al. 1999).
Enhancer RNAs
Another method of regulating accessibility of chromatin at 
the Myod locus is via an enhancer RNA that is transcribed 
from the CE (CEeRNA) (Mousavi et al. 2013; Scionti et al. 
2017). Enhancer RNAs are a relatively recently discovered 
class of non-coding RNAs identified from whole genome 
studies. They are transcribed from active enhancers and 
appear to have important roles in regulating transcrip-
tion (reviewed in Liu 2017). The mechanism by which the 
CEeRNA regulates Myod expression is still being investi-
gated, but it seems to promote accessibility of the Myod 
promoter, since if it is depleted via siRNA then chromatin 
accessibility, as measured by DNAse1 sensitivity, is reduced, 
together with reduced Myod transcription levels (Mousavi 
et al. 2013). Expression of the CEeRNA during differentia-
tion in C2 cells is promoted by binding of Lysine Specific 
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Demethylase 1 (LSD1) to the CE (Fig. 1), whilst in mouse 
embryos a conditional knockout of Lsd1 in muscle progeni-
tor cells results in a strong reduction of CEeRNA expression 
in the limb (Scionti et al. 2017), indicating Lsd1 is involved 
in CEeRNA expression in the embryo. Interestingly, this 
Lsd1 conditional knockout also results in a strong reduction 
of initial Myod expression in the limbs and a mild reduction 
in somites, which recovers later, reminiscent of the Myod 
expression seen when CE is deleted in vivo (Chen and Gold-
hamer 2004). This suggests transcription of the CEeRNA 
is also required for CE activity in driving the initiation of 
Myod expression.
Super‑enhancers
Super enhancers are large regions of the genome that 
are characterised by high levels transcription factor 
occupancy, H3K27ac marks, mediator complex, and 
transcription of multiple enhancer RNAs (Khan et al. 
2018). Interestingly, a region extending approximately 
40–50 kb upstream of Myod, in both mouse and human 
locus, has been described that has characteristics of a 
super-enhancer (Ehrlich et al. 2016; Mousavi et al. 2013), 
which further implicates a larger region beyond 24 kb 
upstream of the Myod TSS in expression regulation 
Table 2  Histone marks identified at the Myod proximal regulatory region (PRR), distal regulatory region (DRR) and core enhancer
Region Histone Type of mark Binding shown by Comments References
PRR H3K4me3 Active ChIP-qPCR in Rhabdomyosar-
coma cells
Taberlay et al. (2011)
H3K27ac Active ChIP-qPCR in C2C12 cells Levels increase as cells differ-
entiate
Hamed et al. (2013)
H4Kac Active ChIP-PCR in mouse embryo 
limbs
Lower levels than at CE Havis et al. (2012)
H3K9ac Active ChIP-qPCR in C2C12 cells Levels increase as cells differ-
entiate
Yang et al. (2011) and Hamed et al. 
(2013)
H3.3 Active ChIP-qPCR in C2C12 cells Lower levels than CE. Levels 
increase as cells differentiate
Yang et al. (2011)
DRR H3K4me3 Active ChIP-qPCR in C2C12 cells Levels increase as cells differ-
entiate
Yang et al. (2011)
H3K27ac Active ChIP-qPCR in C2C12 cells Levels increase as cells differ-
entiate
Hamed et al. (2013)
H3K9ac Active ChIP-qPCR in C2C12 cells Levels increase as cells differ-
entiate
Yang et al. (2011) and Hamed et al. 
(2013)
H3.3 Active ChIP-qPCR in C2C12 cells. Lower levels than CE. Levels 
increase as cells differentiate
Yang et al. (2011)
H3K20me2 Repressive ChIP-qPCR in satellite cells 
isolated from mouse muscle
Levels decrease in Suv4-20h1 
knockout cells
Boonsanay et al. (2016)
H3K9me2 Repressive ChIP-qPCR in C2C12 cells Luo et al. (2017)
CE H3K4me3 Active ChIP-qPCR in C2C12 cells Levels increase as cells differ-
entiate
Scionti et al. (2017) and Yang et al. 
(2011)
H3K27ac Active ChIP-qPCR in and differentiated 
C2C12 cells
Levels increase greatly as cells 
differentiate
Hamed et al. (2013)
H4Kac Active ChIP-PCR in mouse embryo 
limbs
Higher levels than at PRR Havis et al. (2012)
H3K4me1 Enhancer ChIP-qPCR in Rhabdomyosar-
coma cells
Taberlay et al. (2011)
H3K9ac Active ChIP-qPCR in C2C12 cells Levels increase as cells differ-
entiate. Levels decrease when 
MSX1 expressed
Yang et al. (2011), Hamed et al. 
(2013) and Lee et al. (2004)
H3.3 Active ChIP-qPCR in C2C12 Higher levels than DRR and 
PRR. Levels increase as cells 
differentiate
Yang et al. (2011)
H3K9me2 Repressive ChIP-qPCR in C2C12 Levels increase when MSX1 
expressed.
Lee et al. (2004)
HB1 Repressive ChIP-qPCR in C2C12 Levels increase when MSX1 
expressed
Lee et al. (2004)
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(Fig. 1). Interestingly PAX3 has been shown to promote 
chromatin accessibility, and may act to do so in a region 
from the Myod TSS up to approximately 40 kb upstream, 
since in mouse embryoid bodies induced to express Pax3, 
both binding of PAX3 and accessibility of chromatin 
increases in this region during skeletal muscle differen-
tiation (Magli et al. 2019).
Conclusion
At first glance the Myod upstream region, with two main 
enhancer elements may seem uncomplicated. However, 
this belies a complex regulatory landscape where tissue 
and temporal specificity are merged, in the most part, into 
two these elements. This is in contrast to Myf5 regulation, 
which has multiple enhancer regions located in a region 
140 kb upstream of its TSS that drive distinct expression 
patterns in the somite, limb and head, and Myog which 
has just one 133 bp regulatory region located immedi-
ately upstream of its TSS (reviewed in Carvajal and Rigby 
2010). While we have knowledge of many (but, undoubt-
edly, nowhere near all) of the transcription factors that 
bind Myod regulatory elements and the histone marks that 
decorate the region, we are far from understanding the 
details of how they interact with each other to bring about 
the precise spatial and temporal expression of Myod. For 
instance, while mutant studies can show that different tran-
scription factors compensate for each other, what is their 
relative contribution in the wildtype situation? Similarly, 
what is the relative contribution of the CE and DRR and 
(how) do these regions communicate with each other to 
drive precise Myod expression? What is the relationship of 
transcription factor binding with epigenetic marks? Many 
studies have shown a correlation between transcription 
factor binding and epigenetic marks, but which comes 
first and interactions between all of them is yet to be fully 
explored. Non-coding RNAs, including the recent discov-
ery of enhancer RNAs, have added another level of regu-
lation that must be integrated into our picture of how all 
these different factors interact with each other to regulate 
Myod transcription.
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